Anika Therapeutics, Inc. Deferred Tax Expense from Stock Options Exercised
Anika Therapeutics, Inc. (ANIK) reported Deferred Tax Expense from Stock Options Exercised of $4.44 million for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-05-05.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:DeferredTaxExpenseFromStockOptionsExercised · last filed 2014-05-05
- Anika Therapeutics, Inc. deferred tax expense from stock options exercised for the quarter ending 2014-03-31 was $4.44M, a 6762.80% increase year-over-year.
- Anika Therapeutics, Inc. deferred tax expense from stock options exercised for the quarter ending 2013-12-31 was $92.65K.
- Anika Therapeutics, Inc. deferred tax expense from stock options exercised for the quarter ending 2013-09-30 was $756.59K, a 1239.78% increase year-over-year.
- Anika Therapeutics, Inc. deferred tax expense from stock options exercised for the quarter ending 2013-06-30 was -$57.05K.
- Anika Therapeutics, Inc. deferred tax expense from stock options exercised for fiscal 2013 was $856.83K, a 89.37% increase from fiscal 2012.
- Anika Therapeutics, Inc. deferred tax expense from stock options exercised for fiscal 2012 was $452.47K, a 65.02% increase from fiscal 2011.
- Anika Therapeutics, Inc. deferred tax expense from stock options exercised for fiscal 2011 was $274.19K.
| Period end | Deferred Tax Expense from Stock Options Exercised 3 month | Deferred Tax Expense from Stock Options Exercised 6 month | Deferred Tax Expense from Stock Options Exercised 9 month | Deferred Tax Expense from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2014-03-31 | $4.44M 10-Q · filed 2014-05-05 | $4.53M derived: sum of 2 quarters · filed 2014-05-05 | $5.29M derived: sum of 3 quarters · filed 2014-05-05 | $5.23M derived: sum of 4 quarters · filed 2014-05-05 |
| 2013-12-31 | $92.65K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | $849.23K derived: sum of 2 quarters · filed 2014-03-13 | $792.19K derived: sum of 3 quarters · filed 2014-03-13 | $856.83K 10-K · filed 2014-03-13 |
| 2013-09-30 | $756.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $699.54K derived: sum of 2 quarters · filed 2013-11-05 | $764.18K 10-Q · filed 2013-11-05 | $759.86K derived: sum of 4 quarters · filed 2014-05-05 |
| 2013-06-30 | -$57.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $7.60K 10-Q · filed 2013-08-06 | $3.27K derived: sum of 3 quarters · filed 2014-05-05 | $59.74K derived: sum of 4 quarters · filed 2014-05-05 |
| 2013-03-31 | $64.64K 10-Q · filed 2014-05-05 | $60.32K derived: sum of 2 quarters · filed 2014-05-05 | $116.79K derived: sum of 3 quarters · filed 2014-05-05 | |
| 2012-12-31 | -$4.33K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | $52.15K derived: sum of 2 quarters · filed 2014-03-13 | $452.47K 10-K · filed 2014-03-13 | |
| 2012-09-30 | $56.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $456.80K 10-Q · filed 2013-11-05 | ||
| 2012-06-30 | $400.32K 10-Q · filed 2013-08-06 | |||
| 2011-12-31 | $274.19K 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |